Company Description
Merck & Co., Inc. operates as a healthcare company worldwide.
It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.
The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners.
It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications.
The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
| Country | United States |
| Founded | 2000 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 72,000 |
| CEO | Robert M. Davis J.D. |
Contact Details
Address: 2000 Galloping Hill Road Kenilworth, New Jersey 07033 United States | |
| Phone | 908-740-4000 |
| Website | merck.com |
Stock Details
| Ticker Symbol | MRK |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000310158 |
| CUSIP Number | 58933Y105 |
| ISIN Number | US58933Y1055 |
| Employer ID | 22-1918501 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert M. Davis J.D. | Chairman, President and Chief Executive Officer |
| Caroline Litchfield | Executive Vice President and Chief Financial Officer |
| Jennifer L. Zachary | Executive Vice President and General Counsel |
| Dr. Dean Y. Li M.D., Ph.D. | Executive Vice President and President of Merck Research Laboratories |
| Chirfi Guindo | Senior Vice President and Chief Marketing Officer of Human Health |
| Dalton E. Smart III | Senior Vice President of Finance, Principal Accounting Officer and Global Controller |
| David Michael Williams | Executive Vice President and Chief Information and Digital Officer |
| Peter Dannenbaum | Vice President of Investor Relations |
| Lisa LeCointe-Cephas | Senior Vice President and Chief Ethics and Compliance Officer |
| Cristal N. Downing | Executive Vice President and Chief Communications and Public Affairs Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | ARS | Filing |
| Apr 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 11, 2024 | 10-K/A | [Amend] Annual report |
| Apr 1, 2024 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Mar 28, 2024 | PX14A6G | Notice of exempt solicitation submitted by non-management |
| Mar 19, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 19, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 11, 2024 | 4 | Statement of changes in beneficial ownership of securities |
| Feb 26, 2024 | 10-K | Annual Report |